中文摘要：

主要的肝癌症是死亡的最普通的原因之一。为 90% 主要的肝癌症的 Hepatocellular 癌(HCC ) 报道。为有 unresectable 或变形 HCC 的病人，常规化疗具有有限或没有利益。Sorafenib 是唯一的全身的治疗表明一个统计上重要却谦虚的全面幸存好处，导致指向的代理人的一个时代。指向的药的许多临床的试用与在进行中的许多更多被执行了。象 PTK787 一样的一些药在 HCC 的治疗显示出潜在的好处。尽管有这些有希望的突破，有 HCC 的病人仍然有忧郁的预后。最近， everolimus 的阶段 III 试用和 trebananib 的 II 临床的试用没能在先进 HCC 表明有效 antitumor 活动的一个阶段。Sorafenib 仍然在先进 HCC 起一个枢轴的作用，导致进一步的探索施加它的最大的功效。与化疗或 transarterial chemoembolization 指向的联合现在正在被测试并且可能引起进展。象 rapamycin 禁止者的哺乳动物的目标那样的新指向的代理人在 hepatocarcinogenesis 的机制的调查，以及进一步的探索下面。

英文摘要：

Primary liver cancer is one of the commonest causes ofdeath. Hepatocellular carcinoma （HCC） accounts for 90%of primary liver cancers. For patients with unresectable ormetastatic HCC, conventional chemotherapy is of limitedor no benefit. Sorafenib is the only systemic treatmentto demonstrate a statistically significant but modestoverall survival benefit, leading to an era of targetedagents. Many clinical trials of targeted drugs have beencarried out with many more in progress. Some drugs likePTK787 showed potential benefits in the treatment ofHCC. Despite these promising breakthroughs, patientswith HCC still have a dismal prognosis. Recently, both aphase Ⅲ trial of everolimus and a phase Ⅱ clinical trialof trebananib failed to demonstrate effective antitumoractivity in advanced HCC. Sorafenib still plays a pivotalrole in advanced HCC, leading to further explorationsto exert its maximum efficacy. Combinations targetedwith chemotherapy or transarterial chemoembolization isnow being tested and might bring about advances. Newtargeted agents such as mammalian target of rapamycininhibitors are under investigation, as well as furtherexploration of the mechanism of hepatocarcinogenesis.